Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Phase 3 Recruiting
3,680 enrolled
PREDICT
Phase 2 Recruiting
474 enrolled
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Recruiting
12,000 enrolled
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
Phase NA Recruiting
1,000 enrolled
Genetic Testing for the Prevention of Cancer in Indigenous American Communities (JUNIPER Trial)
Phase NA Recruiting
300 enrolled
Identifying and Caring for Individuals With Inherited Cancer Syndrome
Phase NA Recruiting
27,500 enrolled
ACCELERATE
Phase NA Recruiting
200 enrolled
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Phase NA Recruiting
82 enrolled
Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer
Phase NA Recruiting
72 enrolled